SILO
Silo Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.84
+6.98%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.67
From 52W high−84.96%
Volume281434.00
Market cap$3.23M
P/E (TTM)—
P/S (TTM)59.7x
Div yield—
Key dataSep 18, 2026
Open
$1.67
From 52W high
−84.96%
Volume
281434.00
Market cap
$3.23M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.5x
P/E (TTM)
—
RSI (14)
19.2
MomentumView details →
1D Return
+6.98%
YTD Return
−64.90%
SummaryUpdated Jun 1, 2026
Silo Pharma, Inc. (NASDAQ:SILO) is a developmental-stage biopharmaceutical company founded in 2010 and based in Sarasota, Florida. Originally incorporated as Uppercut Brands, Inc., the company changed its name to Silo Pharma in September 2020 and went public in January 2021. The company focuses on developing innovative therapeutics for underserved medical conditions, particularly stress-induced psychiatric disorders, chronic pain conditions, and central nervous system diseases. Silo Pharma distinguishes itself by exploring both traditional pharmaceutical approaches and cutting-edge psychedelic treatments, often incorporating novel drug delivery systems to enhance therapeutic efficacy.
Similar companies
Latest newsMore news →
Silo Pharma, Inc. issued 165,000 shares of common stock to Parkview Consulting LLC in a private placement exempt under Section 4(a)(2) of the Securities Act of 1933, with a 12-month lock-up period, as disclosed in an 8-K filed on August 18, 2026.33d agoSilo Pharma's subsidiary QwikAgents was accepted into Advanced Micro Devices' AMD AI Developer Program.68d ago